isak55 / shutterstock.com
The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.
Session: Strategic steps to take in the wake of uncertain patent eligibility across biopharma
When: 12:45–13:15, November 15
This session kicks off with speakers representing the European Commission, and biotechnology companies Sotio and New England Biolabs. In this session, speakers will assess why it is important to have predictability and uniformity in the global biotech IP sector.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
IP Life Sciences Exchange, Munich, medicine, patent, infringement, Brexit, biopharma
